CellSource CoTSE:4880 -2.15%69 ROE % is 2.37% as of Apr. 2026, which is 88% below its 10-year median of 19.87. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円781.48 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 1,247 Biotechnology companies, CellSource Co ranks better than 79.55% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. CellSource Co's annualized net income for the quarter that ended in Apr. 2026 was 円142 Mil. CellSource Co's average Total Stockholders Equity over the quarter that ended in Apr. 2026 was 円6,005 Mil. Therefore, CellSource Co's annualized ROE % for the quarter that ended in Apr. 2026 was 2.37%.
The historical rank and industry rank for CellSource Co's ROE % or its related term are showing as below:
TSE:4880'
s ROE % Range Over the Past 10 Years
Min: 0.18 Med: 19.87 Max: 63.5
Current: 1.18
During the past 9 years, CellSource Co's highest ROE % was 63.50%. The lowest was 0.18%. And the median was 19.87%.
TSE:4880's ROE % is ranked better than 79.55% of 1247
companies
in the Biotechnology industry
Industry Median: -38.18
vs TSE:4880: 1.18
CellSource Co (TSE:4880) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Apr. 2026) net income data. The Revenue data used here is two times the semi-annual (Apr. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
CellSource Co ROE % Related Terms
CellSource Co ROE % Historical Data
* Premium members only.
The historical data trend for CellSource Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CellSource Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's ROE % distribution charts can be found below:
* The bar in red indicates where CellSource Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Apr. 2026) net income data.
ROE % is displayed in the 30-year financial page.
CellSource Co (TSE:4880) has a ROE % of 2.37% as of Apr. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CellSource Co and its competitors. This is 88% below median its historical median of 19.87. Over the past decade, CellSource Co's ROE % has ranged from 0.18 to 63.50. According to the industry distribution chart, CellSource Co ranks #255 out of 1247 companies in the Biotechnology industry, placing it in the top 20.4%.
Is CellSource Co's ROE % too high?
CellSource Co's current ROE % of 2.37% is 88% below median its 10-year median of 19.87. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 63.50. Based on the distribution chart, CellSource Co ranks #255 out of 1247 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #255 out of 1247 companies for ROE %. This places CellSource Co in the top 20% of its industry — outperforming the majority of peers. Historically, CellSource Co's own ROE % has ranged from 0.18 to 63.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CellSource Co and its competitors. CellSource Co's current ROE % is 2.37%, which is 88% below median its own 10-year median of 19.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.48, compared to a current price of 円319.00 — trading 59.2% below its estimated fair value. The current ROE % is 2.37%, which is 88% below median its 10-year median of 19.87. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current ROE % is 2.37% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円319.00 is trading 59.2% below its estimated GF Value™ of 円781.48.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
ROE %: 2.37% (88% below median its 10-year median of 19.87)
GF Value™: 円781.48 vs. price of 円319.00 (59.2% below fair value)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
